Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.

Abstract: A method for accurately diagnosing an internal fault of an oil-immersed transformer by analyzing content ratios of dissolved gases generated when the internal fault occurs in the oil-immersed transformer is provided. The method diagnoses the internal fault by analyzing the dissolved gases contained in the insulating oil of the oil-immersed transformer for internal fault diagnosis, wherein the method comprises: a first step of extracting H2, CH4, C2H4, and C2H2 from the dissolved gases; a second step of calculating a content ratio (%) of each dissolved gas from the total content of the four dissolved gases selected from the extracted five dissolved gases; and a third step of determining the internal fault of the oil-immersed transformer for diagnosis corresponding to an internal fault region according to content ratio (%) values of the calculated four dissolved gases and predetermined content ratios (%) of the four dissolved gases.

Abstract: A battery management system (BMS) and a method of driving the same are disclosed. In one aspect, the BMS includes a first state of charge (SOC) estimator configured to estimate an SOC of a battery using at least one of i) a charge and discharge current of the battery, ii) a voltage of the battery and iii) a temperature of the battery. The BMS also includes a residual capacity estimator, when the estimated SOC is substantially equal to or less than the reference SOC, configured to estimate a current residual capacity using at least one of i) a reference residual capacity calculated from a reference SOC, ii) the measured battery voltage, iii) a first reference voltage, and iv) a second reference voltage. The BMS further includes a second SOC estimator configured to estimate a current SOC based at least in part on the current residual capacity.

Abstract: The present invention relates to a cosmetic composition which mimics the extracellular matrix to stimulate the regeneration of skin cells, and more particularly to a cosmetic composition which contains active ingredients consisting of low-molecular-weight materials, which easily permeate through the skin, at a composition ratio similar to that in the extracellular matrix. The cosmetic composition stimulates the repair of the skin to maintain homeostasis and is effective for the regeneration of skin cells.

Abstract: A battery management system includes a sensing unit and a main controller unit (MCU) is disclosed. In one aspect, the sensing unit is configured to measure a current value and a voltage value of a battery under a discharge condition of the battery. In addition, the MCU is configured to receive the current and voltage values and further configured to manage capacities of the battery based at least in part on the current and voltage values. In addition, the MCU includes a an unusable capacity calculating unit configured to calculate an unusable capacity corresponding to a portion of a theoretical maximum capacity of the battery that is unusable under the discharge condition, where the unusable capacity is calculated based at least in part on the current value and an internal resistance value of the battery under the discharge condition.

Abstract: The present invention relates to a low noise frequency converter capable of oscillating various frequencies according to the user's selection. The user selects at least one or more frequencies from among a plurality of frequencies. The low noise frequency converter receives a control signal from the user, and oscillates a frequency selected by the user according to the received control signal. The low noise frequency converter uses the oscillated frequencies for frequency conversion.

Abstract: A battery management system for effectively and accurately estimating a state of charge (SOC) of a battery is disclosed. In one aspect, the battery management system includes a main controller unit configured to receive current and voltage data from a sensing unit and calculate an open circuit voltage (OCV) upon determining that a sum of integrated current values exceeds a predetermined value. The battery management system is further configured to estimate the SOC based on the calculated OCV.

Abstract: Disclosed is an electrode member. The electrode member includes a substrate, and an electrode provided in the shape of a mesh on the substrate.

Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: The present invention relates to a cosmetic composition which mimics the extracellular matrix to stimulate the regeneration of skin cells, and more particularly to a cosmetic composition which contains active ingredients consisting of low-molecular-weight materials, which easily permeate through the skin, at a composition ratio similar to that in the extracellular matrix. The cosmetic composition stimulates the repair of the skin to maintain homeostasis and is effective for the regeneration of skin cells.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins as well as their prodrugs are disclosed. Such reverse-turn mimetic structures and prodrugs have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds and prodrugs for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: An after-image prevention apparatus and method for a plasma display panel having a plurality of address electrodes and a plurality of scan and sustain electrodes arranged in pairs and in a zigzag pattern. An average signal level until the current frame from currently input picture data and an average signal level of each cell until the previous frame as stored in a memory section is calculated. The average signal level is compared with the picture data. An attenuation coefficient is generated corresponding to the difference between the average signal level and the picture data. The picture data is multiplied by the attenuation coefficient to output correction data, thereby preventing an after-image phenomenon on the plasma display panel.

Abstract: Disclosed is a plasma display panel, and an apparatus and method for driving the same. In the method of the present invention, an image signal is received and gamma-corrected according to a gamma correction curve. The gamma-corrected image signal is generated as subfield data according to a compressed subfield generation table. The average signal level of the image signal is calculated and correction according to an average signal level correction inverse curve is performed regarding the generation of the subfields for each gray level, and a sustain electrode driving signal and a scan electrode driving signal corresponding to the average signal level are output.

Abstract: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed as well as methods for screening the same to identify biologically active members. The invention also relates to the use of such compounds for inhibiting or treating disorders modulated by Wnt-signaling pathway, such as cancer, especially colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss, or ulcerative colitis.

Abstract: A driving apparatus of a plasma display panel (PDP) and a method for displaying pictures on the plasma display panel, which are capable of increasing the ability to express a low gray scale. Common non-emitted sub-fields are detected, using picture signal data having the maximum level of the gray scale, of all input picture signal data within one frame of the input picture signal data. Sub-fields having higher weights are divided into a plurality of sub-fields having lower weights and the plurality of sub-fields having lower weights are rearranged as sub-fields for expression of gray scale, corresponding to the number of non-emitted sub-fields. In addition, the number of sustains corresponding to the rearranged sub-fields are generated.